The study, conducted on 349 patients in conjunction with the Liverpool Ocular Oncology Centre, set out to determine visual acuity, local tumor control, ocular retention and overall survival after patients received proton beam radiation therapy for melanoma affecting their eyes. The patients chosen were deemed unsuitable for other forms of treatment because of their tumor size and location, with 75 percent of the patients having tumors that extended to within three millimeters of the optic disk, which if affected can cause blindness. The large tumors also posed an increased risk of the tumor returning, retinal detachment and glaucoma.
Of the 346 patients who had the ability to count fingers before treatment began, 79.1 percent of them retained that ability at the five year mark. Before treatment, 212 patients had 20/40 vision, 44.8 percent were able to retain that visual acuity five years following radiation therapy. Overall survival rates based on the cancer spreading to other parts of the body was high with 90 percent of the patients able to stave off further disease when they were checked at the five year milestone.
"What is special is that these good results, similar to other studies, are achieved despite the fact that we reserve proton beam radiation therapy for patients who we feel would not do well with other methods," said Bertil Damato, M.D., Ph.D., F.R.C.Ophth., a doctor at St. Paul's Eye Unit at Royal Liverpool University Hospital in Liverpool, England. "The findings are also interesting because our proton beam has relatively sharp conformal dose characteristics, thereby enhancing its capability for avoiding critical structures, such as the optic disk."
For more information on radiation therapy for head and neck cancers, please visit www.astro.org/patient/treatment_information/ for a free brochure.
To arrange an interview with Dr. Damato or for a copy of the study "Proton Beam Radiotherapy of Chorodial Melanoma: The Liverpool-Clatterbridge Experience," please contact Nick Lashinsky at email@example.com or 1-800-962-7876.
Media interested in registering for ASTRO's 47th Annual Meeting, scheduled for October 16-20, 2005, in Denver should visit http://www.
ASTRO is the largest radiation oncology society in the world, with more than 8,000 members who specialize in treating patients with radiation therapies. As a leading organization in radiation oncology, biology and physics, the Society is dedicated to the advancement of the practice of radiation oncology by promoting excellence in patient care, providing opportunities for educational and professional development, promoting research and disseminating research results and representing radiation oncology in a rapidly evolving socioeconomic healthcare environment.